摘要
近年来,得益于对癌症免疫监视和逃逸机制理解的不断深入及基因转运载体的发展,免疫疗法在临床上取得了一系列的成功。本文将介绍包括慢病毒载体(lentivirus,LV)的基本结构和生活史在内的发展历程。LV应用中的最主要安全性风险来源于具有复制能力的慢病毒载体(replication competent LV,RCL),针对这一问题发展出了一系列新的LV和相应的辅助手段。目前作为癌症免疫疗法主流的过继细胞传输法包括T细胞受体(T cell receptor,TCR)-T细胞和嵌合抗原受体(chimeric antigen receptor,CAR)-T细胞疗法,其中LV已被广泛应用。此外本文还针对LV应用中的一些监管方面的问题及LV的未来发展方向进行探讨。
Recently,due to the advancement in understanding of mechanism of immunological surveillance and escape of cancer as well as the development of gene delivery vector,immunotherapy achieved a number of clinical success. In this review we will overview the progress in research on lentivirus(LV) including its basic structure and life cycle. The main issue of lentivirus in safety comes from the replication competent LV(RCL),therefore iteration vector and other approaches have been developed. Nowadays,LV has been broadly used in the adoptive T-cell transfer therapy,the mainstream of cancer immunotherapy,such as T cell receptor(TCR)-T therapy and chimeric antigen receptor(CAR)-T therapy. The problem in regulation and the future direction of LV vector are also discussed.
作者
邱苏赣
白玉
QIU Su-gan;BAI Yu(Drug Evaluation Center,State Food and Drug Administration,Beijing 100022,China)
出处
《中国生物制品学杂志》
CAS
CSCD
2019年第5期589-593,共5页
Chinese Journal of Biologicals
关键词
肿瘤
免疫疗法
慢病毒载体
Tumor
Immune therapy
Lentivirus vector
